HomeCompareSPKTF vs PFE

SPKTF vs PFE: Dividend Comparison 2026

SPKTF yields 1538.46% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPKTF wins by $883991768.06M in total portfolio value
10 years
SPKTF
SPKTF
● Live price
1538.46%
Share price
$0.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$883991768.11M
Annual income
$783,774,560,703,885.50
Full SPKTF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SPKTF vs PFE

📍 SPKTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPKTFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPKTF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPKTF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPKTF
Annual income on $10K today (after 15% tax)
$130,769.23/yr
After 10yr DRIP, annual income (after tax)
$666,208,376,598,302.60/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SPKTF beats the other by $666,208,376,575,982.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPKTF + PFE for your $10,000?

SPKTF: 50%PFE: 50%
100% PFE50/50100% SPKTF
Portfolio after 10yr
$441995884.08M
Annual income
$391,887,280,365,072.10/yr
Blended yield
88.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SPKTF
No analyst data
Altman Z
3.9
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPKTF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPKTFPFE
Forward yield1538.46%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$883991768.11M$49.6K
Annual income after 10y$783,774,560,703,885.50$26,258.71
Total dividends collected$876714122.30M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SPKTF vs PFE ($10,000, DRIP)

YearSPKTF PortfolioSPKTF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$164,546$153,846.15$9,153$693.39+$155.4KSPKTF
2$2,541,933$2,365,868.50$8,593$849.25+$2.53MSPKTF
3$36,877,139$34,157,271.11$8,336$1,066.78+$36.87MSPKTF
4$502,577,470$463,118,930.88$8,437$1,384.80+$502.57MSPKTF
5$6,436,433,977$5,898,676,084.35$9,013$1,875.40+$6436.42MSPKTF
6$77,488,345,446$70,601,361,090.44$10,306$2,680.72+$77488.34MSPKTF
7$877,278,013,079$794,365,483,451.57$12,820$4,101.38+$877278.00MSPKTF
8$9,343,682,184,854$8,404,994,710,859.21$17,673$6,826.70+$9343682.17MSPKTF
9$93,660,941,503,130$83,663,201,565,336.92$27,543$12,591.86+$93660941.48MSPKTF
10$883,991,768,112,235$783,774,560,703,885.50$49,560$26,258.71+$883991768.06MSPKTF

SPKTF vs PFE: Complete Analysis 2026

SPKTFStock

Spectra Products Inc. manufactures and markets bus and truck transportation safety equipment in Canada and the United States. It offers brake and wheel-end monitoring equipment as an after-market product through transportation dealers, distributors, and direct sales to fleet operators. The company also provides Brake Safe, a visual brake stroke indicator system that permits vehicle drivers and maintenance to visually check the brake adjustment condition of a truck and trailer or bus equipped with an air brake system; and Brake Inspector, an electronic in-cab air brake diagnostic system. In addition, it offers Termin-8r, an anti-corrosion spray lubricant; Zafety Lug Lock that prevents wheel-end lug nuts from loosening leading to wheel damage or loss; Hub Alert, a heat sensitive label, which is applied to each wheel hub of trucks, trailers, buses, and off-road vehicles to provide an early warning of critical temperature threshold levels; and Anti-Seize Cotter Pin, which keeps clevis pins from seizing in slack adjusters. The company was formerly known as Spectra Inc. and changed its name to Spectra Products Inc. in January 2020. Spectra Products Inc. was incorporated in 1994 and is based in Toronto, Canada.

Full SPKTF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SPKTF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPKTF vs SCHDSPKTF vs JEPISPKTF vs OSPKTF vs KOSPKTF vs MAINSPKTF vs JNJSPKTF vs MRKSPKTF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.